Argent BioPharma Finalizes US$5.5 Million CannEpil® Licensing Deal with Splash Beverage Group, Eliminates Major Debt

Licensing Deal De-Risks CannEpil® US Regulatory Development

The binding licensing agreement between Argent BioPharma and Splash Beverage Group marks a pivotal change in Argent’s risk exposure for its CannEpil® program. Under this arrangement, Splash Beverage Group assumes full responsibility for financing and executing US clinical trials—including Phase I and II studies—and filing a New Drug Application (NDA) with the FDA. This shift transfers significant clinical development and regulatory risks to the NYSE American-listed partner, alleviating Argent from substantial operational and financial burdens. The timing aligns strategically with Argent’s planned US national exchange listing, positioning the company as a de-risked asset with regulatory progression managed by an experienced partner.

Argent maintains full economic interest in CannEpil® through ongoing EU-GMP manufacturing services charged on a cost-plus basis with up to a 20% margin, generating continuous revenue irrespective of product approval timing. More importantly, Argent secures a 15% royalty on net revenues for the longer duration of ten years from first sale or patent expiry in each market, ensuring sustained participation in CannEpil®’s commercial success without incurring regulatory or market development costs in the US pharmaceutical sector.

US$5.5 Million Debt Forgiveness Enhances Financial Stability Without Dilution

Forgiveness of US$5.5 million in secured convertible notes held by Mercer Street Global Opportunity Fund significantly deleverages Argent BioPharma’s balance sheet. This milestone was achieved without issuing new shares, thereby avoiding shareholder dilution typically associated with capital raises or debt-to-equity conversions. Eliminating this principal secured debt reduces leverage and removes senior creditor claims on future revenues and assets, providing Argent with greater financial flexibility and less pressure to meet clinical or commercial milestones solely to satisfy creditor demands.

This debt elimination affords Argent strategic breathing room to focus on pipeline advancement and regulatory progress without the immediate burden of large secured liabilities. With a closing cash balance of A$141,000 at the end of June 2026, this debt forgiveness was critical to sustaining operations. Post-quarter, Argent accessed A$350,000 from its A$11 million convertible securities financing facility with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC, followed by an additional A$350,000 drawdown, demonstrating ongoing access to committed capital.

CannPal Acquisition Integrates Advanced Veterinary Therapeutic Program

During the June 2026 quarter, Argent completed acquisition of AusCann Group Holdings' 48% interest in CannPal Animal Therapeutics Pty Ltd and the Neuvis® drug delivery platform, following shareholder approval on 8 April 2026 and formal completion on 13 April 2026. CannPal’s Phase 3 veterinary program targets osteoarthritis pain management in companion animals, offering a near-term commercialization opportunity. This acquisition broadens Argent’s portfolio across human and veterinary indications, supporting the company’s scale and strategic positioning ahead of a US national exchange listing. The Neuvis® platform adds formulation flexibility to enhance performance and lifecycle management across Argent’s pipeline beyond veterinary applications.

Argent regards the CannPal acquisition as a key milestone in its neuro-immune strategy, gaining exposure to a later-stage clinical asset with accelerated commercial potential due to differing veterinary regulatory frameworks. Combining CannPal’s veterinary program with Argent’s human clinical assets diversifies the therapeutic portfolio, reducing concentration risk and increasing potential value inflection points for investors.

Positive Phase 2C Results for CannPal’s CPAT-01 Support Advancement

CannPal Animal Therapeutics’ Phase 2C dose confirmation study for CPAT-01, targeting osteoarthritis pain in dogs, met its primary endpoint with statistically significant pain reduction in aged beagles and no serious adverse events. This outcome supports progression to a Phase 3 pilot field study bridging to commercial populations ahead of pivotal registration trials. The favorable safety profile reduces regulatory risk for subsequent development phases.

CannPal is pursuing partner-led funding for next-stage development and has initiated due diligence discussions with several animal health sector prospects. This mirrors Argent’s strategy with CannEpil® and Splash Beverage Group, transferring development costs and execution risk to established partners. Commercial partners with veterinary distribution networks can accelerate market entry and maximize commercial potential. The Phase 2C success provides a de-risked data package to attract investment for Phase 3 development and commercialization.

Argent’s Proprietary Nano-Engineered Therapeutics and Focused Pipeline

Argent BioPharma’s core expertise lies in proprietary nano-engineered therapeutics designed to rebalance nervous and immune system interactions. Its lead human programs—CannEpil® for drug-resistant epilepsy and CimetrA® for cytokine-driven inflammatory disorders—address significant unmet needs in central nervous system and systemic inflammation diseases. The company’s delivery technologies enhance penetration of the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter patent protection, providing competitive advantages beyond active pharmaceutical ingredient patents.

Argent operates integrated EU-GMP manufacturing, enabling quality control and cost management while generating revenue through services for licensing partners like Splash Beverage Group. The pipeline excludes oncology, focusing on urgent CNS and inflammatory indications. Drug-resistant epilepsy affects about 30% of epilepsy patients unresponsive to conventional treatments, representing a substantial unmet need. Cytokine-driven inflammatory disorders include autoimmune and pain syndromes lacking adequate therapies.

Operational Cash Burn and Convertible Financing Facility Access

Operating cash outflows for the June 2026 quarter totaled A$600,000, including A$100,000 in staff costs and A$48,000 in R&D, with remaining expenses covering manufacturing, operations, and administration. The full-year operating cash burn to 30 June 2026 was A$4,093,000, with staff costs as the largest component at A$1,192,000. This burn rate aligns with typical clinical-stage biotech expenditures on research, regulatory compliance, and personnel. The quarter ended with A$141,000 cash, highlighting reliance on committed financing.

Post-quarter, Argent secured A$350,000 funding from its A$11 million convertible securities financing facility with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC, followed by an additional A$350,000 drawdown. This facility offers financial runway for operations and pipeline progression without immediate equity raises at potentially unfavorable prices. Convertible securities align investor returns with long-term value creation, with conversion prices set above current market levels, incentivizing share price growth. The A$11 million facility, partially drawn, provides a significant buffer for near-term clinical and regulatory milestones in CannEpil® and CannPal programs.

Board Updates and Governance Amid Acquisition Integration

Following the CannPal acquisition, Andrew Chapman joined Argent’s Board as Executive Director. After quarter end, Mr. Chapman transitioned to a Non-Executive Director role, with Mr. Zomer resuming Executive Chairman duties. These changes reflect typical post-acquisition integration, shifting from operational leadership to governance oversight. Mr. Zomer’s return signals progression beyond integration toward growth phases, including regulatory and partnership activities.

During the June 2026 quarter, related party payments totaled A$47,000, comprising executive and non-executive director fees. This compensation level aligns with governance standards expected for clinical-stage biotech companies preparing for US national exchange listings, where institutional investors demand robust board oversight and transparency. Argent’s management and board structure supports its strategic US listing objectives, meeting capital market requirements for related-party disclosures and independent oversight.

Strategic Preparation for US National Exchange Listing and Capital Market Access

Argent’s strategic goals include a US national exchange listing, influencing recent corporate moves. The CannEpil® licensing deal, CannPal acquisition, and secured debt elimination without equity dilution collectively position Argent as an attractive candidate for US capital markets. US exchanges require higher financial disclosure, governance, and operational transparency than ASX, necessitating enhanced reporting and clear pipeline commercialization strategies. Transferring CannEpil® US regulatory risk to an established NYSE American partner reduces execution risk perceived by US institutional investors.

Argent’s diversified pipeline—covering drug-resistant epilepsy, inflammatory disorders, and veterinary osteoarthritis—offers multiple value creation pathways appealing to institutional investors seeking reduced single-asset risk. Proprietary nano-engineered delivery technology, EU-GMP manufacturing, and strategic partnerships with biotech and beverage companies underscore technological differentiation and commercial execution capabilities. Near-term Phase 3 potential from CannPal’s veterinary program combined with long-term human indication development aligns with US investor preferences for visible catalysts and substantial value creation. Argent’s management is executing a multi-year de-risking strategy to maximize attractiveness and valuation for US institutional investors.

Robust Patent Protection and Intellectual Property Ownership

Argent retains full ownership of CannEpil® intellectual property despite granting Splash Beverage Group an exclusive global license. This IP retention is vital for long-term value, as patent-protected assets create competitive barriers against manufacturing, distribution, and sales by competitors. The 15% royalty on net revenues for the longer of ten years from first sale or patent expiry ensures Argent benefits from CannEpil®’s commercial success regardless of patent timelines. Intellectual property ownership of lead assets is a fundamental value driver, aligning shareholder interests with asset value creation.

Argent’s composition-of-matter patent protection extends beyond active pharmaceutical ingredients to specific formulations, delivery methods, and potential combination therapies. This layered protection prolongs patent exclusivity and strengthens competitive moats beyond conventional molecule patents. For investors assessing clinical-stage biotech opportunities, understanding the depth and durability of IP protection is critical for evaluating long-term value potential, especially in regulated markets where patent exclusivity enables premium pricing and market exclusivity.